Metformin and the risk of acidosis in patients with kidney disease
KEY POINT
Use of metformin in patients with an estimated glomerular filtration rate (eGFR) between 30 mL/min/1.73 m2 and 45 mL/min/1.73 m2 did not result in an increased risk of incident acidosis compared with alternative diabetes treatments, according to data from two large retrospective cohort analyses.
SOURCES
Lazarus B, et al. Association of metformin use with risk of lactic acidosis across the range of kidney function: A community-based cohort study. JAMA Intern Med. 2018;[Epub ahead of print].
Good CB, et al. Should metformin be first-line therapy for patients with type 2 diabetes and chronic kidney disease: Informed patients should decide. JAMA Intern Med. 2018;[Epub ahead of print].
FDA. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Accessed June 27, 2018.
